Healio

FDA grants 510(k) clearance for TMS as adjunctive for major depressive disorder in young people

The FDA has granted 510(k) clearance and a label expansion for a transcranial magnetic stimulation device to treat patients ...
The Manila Times

BrainsWay to Host Virtual Analyst & Investor Day to Discuss the Company’s Growth Strategy and Deep TMS™ Treatment December 1, 2025

BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay” or the 'Company”), a global leader in advanced noninvasive brain ...
The Manila Times

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Third Quarter 2025 Financial Results and Provides Corporate Update

NRx has refiled its Abbreviated New Drug Application for KETAFREE™ (preservative free ketamine), received supportive correspondence from FDA, and expects Q2 2026 GDUFA date.HOPE Therapeutics is now ...

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2025 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Q3 2025 Earnings Call Transcript November 17, 2025 Operator: Good morning, ladies and ...
Taiwan News

BrainsWay Launches First Clinical Trial of Deep TMS 360™ System for Alcohol Use Disorder

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive brain stimulation technologies, today announced the launch of a multicenter clinical trial ...
TipRanks on MSN

NRx Pharmaceuticals (NASDAQ: NRXP) Reports Q3 Results and Advances NRX-100 and NRX-101 Regulatory Programs

Austin, Texas, United States, November 17th, 2025, FinanceWire NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 ...
TMCnet

NRx Pharmaceuticals Announces US Food and Drug Administration (FDA) Receipt of ANDA for KETAFREE™, a Preservative-Free IV Ketamine

NRx has applied to FDA for use of KETAFREE™ as a proprietary product name, which is subject to review. KETAFREE™ is the first preservative-free ketamine formulation that does not include potentially ...
Scientific Research Publishing

Exploring the Efficacy of Repetitive Transcranial Magnetic Stimulation in Treating Vestibular Migraine and Its Clinical Prospects ()

Vestibular Migraine (VM) is a common clinical neurological disorder characterized by recurrent episodes of dizziness and headaches. It has a significant genetic predisposition and a high morbidity and ...

Acquisition of Kadima Neuropsychiatry Institute for CNS & Psychedelic Research Planned; New Drug Application for Treatment of Suicidal Depression: NRx Pharmaceuticals NRXP

Developing NRX-101, an FDA-Designated Investigational Breakthrough Therapy for Suicidal Treatment-Resistant Bipolar Depression and Chronic Pain. - Designed to Help Address the Needs of Over 13 Million ...

Biomednewsbreaks - Nrx Pharmaceuticals, Inc. (NASDAQ: NRXP) Reports Q3 Results And Advances NRX-100 And NRX-101 Regulatory Programs

Reports Q3 Results And Advances NRX-100 And NRX-101 Regulatory Programs. NRx Pharmaceuticals (NASDAQ: NRXP) reported third-quarter 2025 results and outlined progress across its clinical programs, noti ...
Le Lézard

Main Line Psychiatric Practice Expands Comprehensive Mental Health Care for Autism and ADHD

Specialized Medication Management: Autistic and ADHD individuals often respond differently to psychiatric medications than neurotypical individuals. The practice's clinicians bring expertise in ...
Frontiers

From the Cerebellum Networking to Brain Dynamics Function

Recent advances in understanding the brain’s dynamic functioning have been achieved through a wide range of experiments conducted across multiple levels of ...